Mersana Therapeutics is a clinical stage biopharmaceutical company focused on developing antibody drug conjugates (ADCs) for cancer patients. Co.'s platforms including Dolaflexin and Dolasynthen, deliver its auristatin DolaLock payload, as well as Immunosynthen, which delivers its stimulator of interferon genes (STING) agonist ImmunoLock payload. Co.'s product candidates include: upifitamab rilsodotin (UpRi), which is a Dolaflexin ADC targeting NaPi2b, an antigen expressed in ovarian cancer and other cancers; and XMT-1592, which is a Dolasynthen ADC targeting NaPi2b-expressing tumor cells.